TREACE MEDICAL CONCEPTS INC
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
TMCI$4.88+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders' Equity
(in thousands, except share amounts)
| Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||
| Common Stock · Paid-In · Accumulated · Comprehensive · Treasury · Stockholders’ | |||||||
| Outstanding Shares | Amount | Capital | Deficit | Income (Loss) | Stock | Equity | |
| Balances at December 31, 2023 | 61,749,654 | $62 | $271,973 | $(134,247) | $163 | $(13) | $137,938 |
| Issuance of common stock upon exercise of stock options | 20,294 | — | 52 | — | — | — | 52 |
| Issuance of common stock for vesting of restricted stock units | 177,610 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 7,408 | — | — | — | 7,408 |
| Net loss | — | — | — | (18,676) | — | — | (18,676) |
| Unrealized loss on available-for-sale marketable securities | — | — | — | — | (94) | — | (94) |
| Shares directly withheld from employees for tax payment | (18,386) | — | — | — | — | (237) | (237) |
| Balances at March 31, 2024 | 61,929,172 | $62 | $279,433 | $(152,923) | $69 | $(250) | $126,391 |
| Issuance of common stock upon exercise of stock options | 209,288 | — | 311 | — | — | — | 311 |
| Issuance of common stock for vesting of restricted stock units | 36,781 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 6,740 | — | — | — | 6,740 |
| Net loss | — | — | — | (21,206) | — | — | (21,206) |
| Unrealized loss on available-for-sale marketable securities | — | — | — | — | (95) | — | (95) |
| Balances at June 30, 2024 | 62,175,241 | $62 | $286,484 | $(174,129) | $(26) | $(250) | $112,141 |
| Issuance of common stock upon exercise of stock options | 35,371 | — | 8 | — | — | — | 8 |
| Issuance of common stock for vesting of restricted stock units | 64,759 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 7,900 | — | — | — | 7,900 |
| Net loss | — | — | — | (15,360) | — | — | (15,360) |
| Unrealized gain on available-for-sale marketable securities | — | — | — | — | 217 | — | 217 |
| Balances at September 30, 2024 | 62,275,371 | $62 | $294,392 | $(189,489) | $191 | $(250) | $104,906 |
| Balances at December 31, 2022 | 55,628,208 | $55 | $145,221 | $(84,720) | $(27) | $— | $60,529 |
| Issuance of common stock upon exercise of stock options | 125,890 | — | 352 | — | — | — | 352 |
| Issuance of common stock for vesting of restricted stock units | 50,415 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 2,692 | — | — | — | 2,692 |
| Issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million | 5,476,190 | 6 | 107,521 | — | — | — | 107,527 |
| Net loss | — | — | — | (13,454) | — | — | (13,454) |
| Unrealized loss on available-for-sale marketable securities | — | — | — | — | (29) | — | (29) |
| Balances at March 31, 2023 | 61,280,703 | $61 | $255,786 | $(98,174) | $(56) | $— | $157,617 |
| Issuance of common stock upon exercise of stock options | 205,244 | 1 | 1,179 | — | — | — | 1,180 |
| Issuance of common stock for vesting of restricted stock units | 42,462 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 3,596 | — | — | — | 3,596 |
| Net loss | — | — | — | (12,271) | — | — | (12,271) |
| Unrealized loss on available-for-sale marketable securities | — | — | — | — | (163) | — | (163) |
| Balances at June 30, 2023 | 61,528,409 | $62 | $260,561 | $(110,445) | $(219) | $— | $149,959 |
| Issuance of common stock upon exercise of stock options | 46,001 | — | 159 | — | — | — | 159 |
| Issuance of common stock for vesting of restricted stock units | 32,516 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 5,192 | — | — | — | 5,192 |
| Net loss | — | — | — | (17,521) | — | — | (17,521) |
| Unrealized gain on available-for-sale marketable securities | — | — | — | — | 71 | — | 71 |
| Balances at September 30, 2023 | 61,606,926 | $62 | $265,912 | $(127,966) | $(148) | $— | $137,860 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.